US FDA’s Slow Start To Approvals In 2019: Don’t Panic
US FDA approved just six new molecular entities in the first quarter of 2019, which seems like quite a letdown after a record-setting year in 2018. But don’t despair: the pattern of NME approvals was back-loaded a year ago – and should be again this year.
You may also be interested in...
Scott Gottlieb is leaving after a record number of drug approvals. If history is any guide, his successor will likely preside over a dip in output.
Years of regulatory fine-tuning culminated in record low average time to approval of 9.9 months for novel agents at US FDA’s drug center.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.